Latest News - Glaukos Corporation

Wednesday, January 10, 2018 | Clinical Trials, Glaucoma, Glaukos Corporation, MIGS

Glaukos' iDose Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile in 12-Month Interim Cohort

Glaukos announced that its travoprost Intraocular Implant with the iDose delivery system continued to provide sustained reduction in IOP in a 12-month interim cohort of patients in its U.S. investigat…

Read the full story

Wednesday, January 03, 2018 | Glaucoma, Glaukos Corporation

Glaukos Submits IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System

Glaukos announced that it has submitted an investigational device exemption (IDE) application to the FDA seeking authorization to study its iStent infinite Trabecular Micro-Bypass System. The iSten…

Read the full story

Wednesday, January 03, 2018 | Glaucoma, Glaukos Corporation, MIGS

Glaukos Submits IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System

Glaukos announced that it has submitted an investigational device exemption (IDE) application to the FDA seeking authorization to study its iStent infinite Trabecular Micro-Bypass System. The iSte…

Read the full story

Wednesday, December 27, 2017 | Glaucoma, Glaukos Corporation

Glaukos Announces Submission of Premarket Approval Application for the iStent Inject Trabecular Micro-Bypass

Glaukos announced that it has submitted a premarket approval (PMA) application to the FDA for the iStent inject Trabecular Micro-Bypass Stent. The iStent inject is designed to improve aqueous humor…

Read the full story

Tuesday, December 19, 2017 | Clinical Trials, Glaukos Corporation

Glaukos to Begin Randomized U.S. IDE Pivotal Clinical Trial for the iStent SA System

Glaukos announced that the FDA is allowing the company to move forward with a US investigational device exemption (IDE) pivotal study of its iStent SA Trabecular Micro-Bypass System. The iStent SA …

Read the full story

Thursday, November 30, 2017 | Patents, Glaukos Corporation

Glaukos Announces Issuance of New U.S. Patent

Glaukos announced that the United States Patent and Trademark Office has issued U.S. Patent No. 9,827,143 to the company. Entitled “Shunt Device and Method for Treating Ocular Disorders”, …

Read the full story

Friday, October 06, 2017 | Conferences, Glaukos Corporation

Glaukos iStent Products to be Showcased at European Society of Cataract and Refractive Surgery

Glaukos announced that various key opinion leader presentations and electronic posters will feature its iStent Trabecular Micro-Bypass and iStent inject Trabecular Micro-Bypass products at the upcomin…

Read the full story

Wednesday, June 21, 2017 | Clinical Trials, Glaucoma, Glaukos Corporation

Study: Combining Implantation of Glaukos iStent inject with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile

Glaukos announced that a study of 53 open-angle glaucoma subjects recently published in Clinical & Experimental Ophthalmology showed that the iStent inject Trabecular Micro-Bypass, combined with t…

Read the full story

Tuesday, May 23, 2017 | Medical Studies, Glaukos Corporation

Study Reveals Potential Cost Efficiency of Using Two Glaukos iStent Trabecular Micro-Bypass Stents to Treat Elevated IOP

Glaukos announced that an analysis published in the Journal of Medical Economics evaluating various options for treating elevated IOP in open-angle glaucoma patients showed that two iStent Trabecular …

Read the full story

Wednesday, May 03, 2017 | Clinical Trials, Glaukos Corporation

Glaukos Completes Patient Enrollment in Phase II Clinical Trial for iDose Travoprost Intraocular Implant in Glaucoma Patients

Glaukos Corporation announced the completion of patient enrollment in the investigational new drug (IND) phase 2 study of its Travoprost intraocular implant with the iDose delivery system in patients …

Read the full story

Friday, April 14, 2017 | Medical Studies, Glaukos Corporation

International Study Shows Two Glaukos iStent Trabecular Micro-Bypass Stents and One Topical Medication Deliver Sustained IOP Reduction

Glaukos announced that a study published in Clinical Ophthalmology showed that two iStent Trabecular Micro-Bypass Stents and one topical ocular hypotensive medication achieved a 38% reduction in mean …

Read the full story

Thursday, April 13, 2017 | Acquisitions/Mergers, Glaucoma, Glaukos Corporation, MIGS

Glaukos Corporation Acquires IOP Sensor System from DOSE Medical

Glaukos announced that it has acquired the IOP sensor system assets and related liabilities from DOSE Medical Corporation for $5.5 million in cash, plus performance-based consideration of up to $9.5 m…

Read the full story

Thursday, March 16, 2017 | Glaucoma, Glaukos Corporation, MIGS

Glaukos Announces Five-Year Extensions for Three Category III CPT Codes Related to Microinvasive Glaucoma Surgery

Glaukos announced that the Current Procedural Terminology (CPT) Editorial Panel of the American Medical Association has granted 5-year extensions to three Category III CPT codes that describe insertio…

Read the full story

Wednesday, February 22, 2017 | Management/Leadership, Glaukos Corporation

L. Jay Katz, MD, Joins Glaukos Corporation as Chief Medical Officer

Glaukos announced that L. Jay Katz, MD, FACS, has joined the company as Chief Medical Officer. Dr. Katz is currently a practicing ophthalmologist, the Director of Glaucoma Service at Wills Eye Hospita…

Read the full story

Thursday, February 16, 2017 | Clinical Trials, Glaukos Corporation, MIGS

Glaukos Completes Patient Enrollment in Pivital Phase of US IDE Clinical Trial for iStent Supra

Glaukos announced the completion of patient enrollment in the pivotal phase of its FDA investigational device exemption (IDE) trial for the iStent Supra Suprachoroidal Micro-Bypass Stent. The iSten…

Read the full story
Load More